Novus Therapeutics Inc (Nasdaq:NVUS) Lowers The 52 Week Low


Novus Therapeutics Inc (Nasdaq:NVUS)

December 5th, 2018
Amidst falling markets Novus Therapeutics Inc fell $0.22 Tuesday, a 6.61% drop, closing at $3.11. As well as the drop in value, Novus Therapeutics Inc hit a new 52 week low of $3.02, breaking the previous low of $3.22 from earlier this month. Novus Therapeutics Inc bounced 17.22% between low and high.

NVUS was outperformed by the rest of the Healthcare sector which went down just 2.30%.

Market Sectors

The market sectors were mixed Wednesday with a majority of the sectors trending down. Utilities saw the biggest increase of the day (0.15%), while Financials saw the biggest drop (4.40%). Healthcare has seen the biggest year-to-date gain at 13%. The biggest loss this year has been the Communication Services sector declining 13%.

Utilities saw the biggest turnaround from its 5-day performance of 2.31%, as it went up 0.15%. Industrials and Consumer Discretionary experienced turn arounds from their five day positive performance, Industrials with a drop of 4.35%.

Sector Breakdown

  • Utilities went up with a 0.15% change.
  • Real Estate went down with a -1.26% change.
  • Consumer Staples went down with a -1.63% change.
  • Healthcare went down with a -2.30% change.
  • Energy went down with a -2.93% change.
  • Materials went down with a -3.08% change.
  • Communication Services went down with a -3.14% change.
  • Information Technology went down with a -3.86% change.
  • Consumer Discretionary went down with a -3.91% change.
  • Industrials went down with a -4.35% change.
  • Financials went down with a -4.40% change.

Novus Therapeutics Inc Info

As of May 10, 2017, Tokai Pharmaceuticals, Inc. was acquired by Otic Pharma Ltd., in a reverse merger transaction. Tokai Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for prostate cancer and other hormonally-driven diseases. Its lead drug candidate is galeterone, an oral small molecule that is in various clinical trials for the treatment of patients with metastatic castration-resistant prostate cancer. The company’s androgen receptor degradation agents drug discovery program is focused on identifying and developing compounds for patients with androgen receptor signaling diseases, including prostate cancer. Tokai Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Boston, Massachusetts.

All amounts in USD unless otherwise indicated
NVUS daily update

NVUS daily update
NVUS daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.